Why the study?
Coxsackievirus A6 is a major cause of hand, foot, and mouth disease outbreaks, but no effective vaccine or antiviral treatments are currently available.
Does RT-RPA-LFS provide accurate detection of Coxsackievirus A6 compared to qPCR in clinical samples?
Does RT-RPA-LFS provide accurate detection of Coxsackievirus A6 compared to qPCR in clinical samples?
The RT-RPA-LFS assay offers a rapid, simple, and highly accurate point-of-care diagnostic tool for Coxsackievirus A6 without the need for expensive equipment.
May enable rapid CVA-6 detection; leaves open prospective validation before clinical use.
Hand, foot, and mouth disease (HFMD) is a common infectious disease affecting mainly children under 5 years of age. Coxsackievirus A6 (CVA-6), a major causative pathogen of HFMD, has caused outbreaks in recent years. Currently, no effective vaccine or antiviral treatments are available. In this study, one-step reverse-transcription recombinase polymerase amplification (RT-RPA), combined with a disposable lateral flow strip (LFS) assay, was developed to detect CVA-6. This assay can be performed in less than 35 min at 37°C without expensive instruments, and the result can be observed directly with the naked eye. The sensitivity of the RT-RPA-LFS was 10 copies per reaction, which was comparable to that of the conventional real-time quantitative polymerase chain reaction (qPCR) assays. Moreover, the assay specificity was 100%. The clinical performance of the RT-RPA-LFS assay was evaluated using 142 clinical samples, and the coincidence rate between RT-RPA-LFS and qPCR was 100%. Therefore, our RT-RPA-LFS assay provides a simple and rapid approach for point-of-care CVA-6 diagnosis.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: